MRK vs NEOG
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. NEOG: Neogen provides essential diagnostic and safety solutions to protect the global food supply chain and enhance animal health and welfare.
Side-by-side fundamentals
| Metric | MRK | NEOG | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $130.20 | $12.04 | |
| Market cap as of 2026-08-03 | $321.6B | $2.6B | |
| P/E as of 2026-08-03 | 36.63 | n/a | |
| PEG as of 2026-08-03 | 4.91 | n/a | |
| Net margin as of 2026-08-03 | +13.6% | -69.9% | MRK higher |
| Gross margin as of 2026-08-03 | +78.1% | +45.2% | MRK higher |
| Operating margin as of 2026-08-03 | +18.2% | -64.3% | MRK higher |
| ROE as of 2026-08-03 | +17.9% | -29.0% | MRK higher |
| ROA as of 2026-08-03 | +7.0% | -18.0% | MRK higher |
| Debt / equity as of 2026-08-03 | 1.07 | 0.38 | NEOG lower |
| Revenue growth (YoY) as of 2026-08-03 | +2.9% | -3.9% | MRK higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +1.9% | MRK higher |
| Dividend yield as of 2026-08-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.27 | 0.38 | |
| 1-year return as of 2026-07-31 close | +66.7% | +158.9% | NEOG higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.